Brief: Ikena Oncology Presents Preclinical Data On Ik-595, Best-In-Class Next-Generation Mek-Raf Complex Inhibitor, In Plenary Session At AACR Special Conference On Ras Targeting
07/03/2023 13:20
March 7 (Reuters) - Ikena Oncology Inc IKNA.O :
* IKENA ONCOLOGY PRESENTS PRECLINICAL DATA ON IK-595,
BEST-IN-CLASS NEXT-GENERATION MEK-RAF COMPLEX INHIBITOR, IN
PLENARY SESSION AT AACR SPECIAL CONFERENCE ON RAS TARGETING
Source text for Eikon: ID:nGNX5G4NtG
Further company coverage: IKNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImageneBio
See all newsU.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Brief: ImageneBio Inc - On Oct 23, Elects Not To Renew Agreement With Miragene - SEC Filing
ImageneBio Inc expected to post a loss of $1.56 a share - Earnings Preview
Brief: Ikena Oncology Announces Stockholder Approval Of Merger With Inmagene Biopharmaceuticals